Approval Milestone Sample Clauses

Approval Milestone. Within thirty (30) days of the achievement of the Approval Milestone Event (as defined in the Equity Agreement), Ampliphi will pay to Intrexon, according to the timelines and procedures set forth in the Equity Agreement, one of the following: (i) [*****] in cash, or (ii) the Approval Milestone Shares (as defined in the Equity Agreement).
AutoNDA by SimpleDocs
Approval Milestone. Within thirty (30) days after the date on which Ligand receives notice that the United States Food and Drug Administration ("FDA") has given final approval of the labeling for the Biologics License Application ("BLA") for OntakO, Ligand shall issue that number of shares (the "Approval Shares") of its voting common stock to Lilly as shall equal the sum of $10 million divided by the average trading price of Ligand's voting common stock over the twenty (20) consecutive trading days immediately preceding the date which is five (5) consecutive days prior to the date the notice referred to above is received.
Approval Milestone. Within thirty (30) days after the date on which Ligand receives notice that the United States Food and Drug Administration ("FDA") has given final approval of the labeling for the *** Ligand shall issue that number of shares (the "Approval Shares") of its voting common stock to Lilly as shall equal the sum of $10 million divided by the average trading price of Ligand's voting common stock over the twenty (20) consecutive trading days immediately preceding the date which is five (5) consecutive days prior to the date the notice referred to above is received.
Approval Milestone. BioForm shall pay to Supplier a milestone payment equal to [****] upon BioForm receiving the first PMA approval from the FDA to market and sell the Company Product in any application within the Field in the United States.
Approval Milestone. Within ten (10) Business Days of the occurrence of the Approval Milestone during the Milestone Period, Buyer shall provide notice to the Stockholder Representative that the Approval Milestone has occurred. From and after the Effective Time and until the earlier of the achievement of the Approval Milestone or the expiration of the Milestone Period, (A) Buyer shall provide the Stockholder Representative, on an biannual basis, a written report covering Buyer’s activities for the preceding period with respect to the Company Milestone Products, and (B) upon reasonable request to Buyer by the Stockholder Representative, made no more than twice per calendar year, Buyer shall meet with the Stockholder Representative, at Buyer’s offices or via telephone or video conference, to provide verbal updates regarding the development status of the Company Milestone Products.
Approval Milestone. Within ten (10) business days after the receipt by Amgen (or any of its Affiliates or Sublicensees) of the first Regulatory Approval of an [*****] for the first Product by the applicable Regulatory Authority in any Major Market (the “Approval Milestone”), Amgen shall notify Company in writing of such occurrence. Thereafter, Amgen will pay to the Company milestone payment of an amount of cash equal to [*****] Dollars ($[*****]) (the “Milestone Payment”) within forty five (45) days of its delivery of notice thereof. The Milestones Payment is non-creditable and non-refundable and shall be due and payable upon the occurrence of the Approval Milestone regardless of any failure by Amgen to provide the notice required by Section 7.1(b). For clarity, the Milestone Payment is payable only once.
Approval Milestone. Within [*****] following Regulatory Approval in Defiante’s name of the Product for the HAE Indication by the EMA, Defiante shall pay to Dyax a one-time milestone payment in the amount of [*****].
AutoNDA by SimpleDocs
Approval Milestone. Within [*****] following the first Regulatory Approval of the Product in the Field in any country of the Additional Defiante Territory, Defiante shall pay to Dyax a one-time milestone payment in the amount of [*****].
Approval Milestone. Hoth will pay Chelexa a one-time cash fee of $3.5 million upon either (i) the first license in the U.S., any U.S. territory or the European Union to make, use and sell a Licensed Product in such country or territory, or (ii) the receipt of approval from the United Stated Federal Drug Administration (FDA) to make, use and sell a Licensed Product.
Approval Milestone. Clovis shall pay Strata Oncology a one-time fee upon the first Approval of the Clovis Drug Candidate for use for the Named Indication, which fee shall be based on the Order to Approval of the Clovis Drug Candidate (the “Milestone Fee”). Clovis shall not be obligated to pay the Milestone Fee unless the Strata Enrolled Patient Contribution is at least [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO THE RULES APPLICABLE TO SUCH CONFIDENTIAL TREATMENT REQUEST. Execution Version [***]. If the Strata Enrolled Patient Contribution is at least [***], then Clovis shall pay the Milestone Fee to Strata Oncology as follows:
Time is Money Join Law Insider Premium to draft better contracts faster.